434P CodeBreaK 101 subprotocol H: Phase Ib study evaluating combination of sotorasib (Soto), a KRASG12C inhibitor, and panitumumab (PMab), an EGFR inhibitor, in advanced KRAS p.G12C-mutated colorectal cancer (CRC)
Marwan Fakih, Gerald S. Falchook, David S. Hong, Rona Yaeger, Emily Chan, Omar Mather, Panli Cardona, Tian Dai, John H. Strickler
Topics & Concepts
MedicineKRASRashColorectal cancerAdverse effectInternal medicinePanitumumabOncologyCancerGastroenterologyColorectal Cancer Treatments and StudiesLung Cancer Treatments and MutationsHER2/EGFR in Cancer Research